Earnings per share of $0.07433, surpassing the estimated -$0.01, indicating a significant improvement in financial health.
Revenue reached approximately $8.84 million, significantly exceeding the estimated $5.90 million due to increased sales of SRT and IG-SRT units.
Notable financial metrics including a price-to-earnings (P/E) ratio of approximately 12.78 and a strong current ratio of 10.52, showcasing the company’s robust liquidity and market valuation.
Sensus Healthcare, Inc. (NASDAQ:SRTS) specializes in providing non-invasive treatment solutions for non-melanoma skin cancers and keloids using superficial radiotherapy (SRT). The company has shown remarkable financial performance in the third quarter of 2024, reporting earnings per share of $0.07433, which surpassed the estimated -$0.01. This achievement highlights a significant improvement in the company’s financial health.
The company’s revenue for the quarter reached approximately $8.84 million, significantly exceeding the estimated $5.90 million. This growth is attributed to increased sales of their SRT and IG-SRT units, as highlighted by Zacks. In comparison to the same quarter last year, where the company reported a loss of $0.09 per share, this marks a notable turnaround. The adjusted EBITDA also improved to $1.6 million from a negative $1.7 million in the previous year.
Sensus Healthcare’s financial metrics further illustrate its strong performance. The company has a price-to-earnings (P/E) ratio of approximately 12.78, indicating the market’s valuation of its earnings. Its price-to-sales ratio stands at about 2.89, suggesting how much investors are willing to pay per dollar of sales. The enterprise value to sales ratio is around 2.36, reflecting the company’s total valuation relative to its sales.
The company’s enterprise value to operating cash flow ratio is approximately 36.63, showing how its valuation compares to its cash flow generation. The earnings yield is about 7.83%, providing insight into the return on investment for shareholders. Additionally, Sensus Healthcare maintains a low debt-to-equity ratio of 0.012, indicating minimal reliance on debt financing, and a strong current ratio of 10.52, suggesting robust liquidity and the ability to cover its short-term liabilities.
Sensus Healthcare has also signed a Fair Deal Agreement with Platinum Dermatology, a prominent dermatology network operating 130 clinics across the United States. This strategic partnership is expected to further enhance the company’s market presence and drive future growth. The company is set to discuss these results further in a conference call scheduled for 4:30 p.m. Eastern time today.
